RVPHW: Reviva Pharmaceuticals Holdings Inc. Stocks News on August 13, 2025

RVPHW

MT Newswires

2 months ago

Reviva Pharmaceuticals Prices $10 Million Public Offering

Reviva Pharmaceuticals Holdings, Inc. Announces Pricing of $10 Million Public Offering

RVPHW

GlobeNewswire

2 months ago

Reviva Pharmaceuticals Holdings, Inc. Announces Pricing of $10 Million Public Offering

Reviva Pharmaceuticals Holdings, Inc. Announces Proposed Public Offering

RVPHW

GlobeNewswire

2 months ago

Reviva Pharmaceuticals Holdings, Inc. Announces Proposed Public Offering

Reviva to Participate in the H.C. Wainwright 6th Annual Neuro Perspectives Hybrid Conference

RVPHW

GlobeNewswire

2 months ago

Reviva to Participate in the H.C. Wainwright 6th Annual Neuro Perspectives Hybrid Conference

RVPH: Open Label Extension Results & Key Opinion Leader Discussion

RVPHW

Zacks Small Cap Research

2 months ago

RVPH: Open Label Extension Results & Key Opinion Leader Discussion

Reviva Announces Positive Full Dataset for 1-Year Phase 3 RECOVER Open Label Extension Study Evaluating Brilaroxazine in Schizophrenia

RVPHW

GlobeNewswire

2 months ago

Reviva Announces Positive Full Dataset for 1-Year Phase 3 RECOVER Open Label Extension Study Evaluating Brilaroxazine in Schizophrenia

RVPHW

Zacks Small Cap Research

3 months ago

RVPH: 1Q:25 Results

Reviva to Participate in Upcoming Investor Conferences in May 2025

RVPHW

GlobeNewswire

3 months ago

Reviva to Participate in Upcoming Investor Conferences in May 2025

Reviva Reports First Quarter 2025 Financial Results and Recent Business Highlights

RVPHW

GlobeNewswire

3 months ago

Reviva Reports First Quarter 2025 Financial Results and Recent Business Highlights

Reviva to Participate in the A.G.P. Healthcare Company Showcase

RVPHW

GlobeNewswire

3 months ago

Reviva to Participate in the A.G.P. Healthcare Company Showcase

Reviva to Participate in the Citizens Life Sciences Conference

RVPHW

GlobeNewswire

3 months ago

Reviva to Participate in the Citizens Life Sciences Conference

Reviva to Present Late-Breaking Poster on the RECOVER Long-term Open Label Extension Trial for Brilaroxazine in Schizophrenia at the 2025 ASCP Annual Meeting

RVPHW

GlobeNewswire

4 months ago

Reviva to Present Late-Breaking Poster on the RECOVER Long-term Open Label Extension Trial for Brilaroxazine in Schizophrenia at the 2025 ASCP Annual Meeting

RVPH: M&A Deals Highlight Brilaroxazine Value

RVPHW

Zacks Small Cap Research

4 months ago

RVPH: M&A Deals Highlight Brilaroxazine Value

Reviva Reports Full Year 2024 Financial Results and Recent Business Highlights

RVPHW

GlobeNewswire

4 months ago

Reviva Reports Full Year 2024 Financial Results and Recent Business Highlights

Reviva to Present Brilaroxazine Topline Data for Long-Term OLE Portion of RECOVER Study in Schizophrenia at 2025 SIRS Congress

RVPHW

GlobeNewswire

4 months ago

Reviva to Present Brilaroxazine Topline Data for Long-Term OLE Portion of RECOVER Study in Schizophrenia at 2025 SIRS Congress

Reviva to Participate in the Oppenheimer 35th Annual Healthcare Life Sciences Conference

RVPHW

GlobeNewswire

6 months ago

Reviva to Participate in the Oppenheimer 35th Annual Healthcare Life Sciences Conference

Reviva to Participate in the 2025 BIO CEO & Investor Conference

RVPHW

GlobeNewswire

6 months ago

Reviva to Participate in the 2025 BIO CEO & Investor Conference

Reviva to Participate in the Lytham Partners 2025 Investor Healthcare Summit

RVPHW

GlobeNewswire

7 months ago

Reviva to Participate in the Lytham Partners 2025 Investor Healthcare Summit

RVPHW

Zacks Small Cap Research

8 months ago

RVPH: Preliminary OLE Readout

Applied Therapeutics Appoints John H. Johnson as Executive Chairman

RVPHW

GlobeNewswire

8 months ago

Applied Therapeutics Appoints John H. Johnson as Executive Chairman

Reviva Pharmaceuticals Strengthens Financial Position with Offering

RVPHW

TipRanks

8 months ago

Reviva Pharmaceuticals Strengthens Financial Position with Offering

RVPHW

MT Newswires

8 months ago

Top Midday Decliners

RVPHW

MT Newswires

8 months ago

Reviva Pharmaceuticals Prices $18 Million Public Offering

Reviva Announces Proposed Public Offering

RVPHW

GlobeNewswire

8 months ago

Reviva Announces Proposed Public Offering

RVPHW

MT Newswires

8 months ago

Reviva Pharmaceuticals Reports Positive Topline Phase 3 Data on Brilaroxazine for Treating Schizophrenia

Reviva Announces Positive Preliminary Topline Data for the Long-Term Open Label Extension Portion of the Phase 3 RECOVER Study Evaluating Brilaroxazine in Schizophrenia

RVPHW

GlobeNewswire

8 months ago

Reviva Announces Positive Preliminary Topline Data for the Long-Term Open Label Extension Portion of the Phase 3 RECOVER Study Evaluating Brilaroxazine in Schizophrenia

RVPHW

Zacks Small Cap Research

9 months ago

RVPH: Year-End OLE Update

Reviva Reports Third Quarter 2024 Financial Results and Recent Business Highlights

RVPHW

GlobeNewswire

9 months ago

Reviva Reports Third Quarter 2024 Financial Results and Recent Business Highlights

Reviva Announces Enrollment Update for Open Label Extension Study Evaluating Brilaroxazine in Schizophrenia

RVPHW

GlobeNewswire

9 months ago

Reviva Announces Enrollment Update for Open Label Extension Study Evaluating Brilaroxazine in Schizophrenia

Reviva to Present Positive Speech Latency Data for Brilaroxazine in Schizophrenia From the Phase 3 RECOVER Trial at the CNS Summit 2024

RVPHW

GlobeNewswire

9 months ago

Reviva to Present Positive Speech Latency Data for Brilaroxazine in Schizophrenia From the Phase 3 RECOVER Trial at the CNS Summit 2024

Reviva to Participate in the UBS Global Healthcare Conference

RVPHW

GlobeNewswire

9 months ago

Reviva to Participate in the UBS Global Healthcare Conference

Reviva to Participate in the 2024 Maxim Healthcare Virtual Summit

RVPHW

GlobeNewswire

10 months ago

Reviva to Participate in the 2024 Maxim Healthcare Virtual Summit

Reviva to Participate in the 3rd Annual ROTH Healthcare Opportunities Conference

RVPHW

GlobeNewswire

10 months ago

Reviva to Participate in the 3rd Annual ROTH Healthcare Opportunities Conference

Reviva Pharmaceuticals to Participate in the Lytham Partners Fall 2024 Investor Conference

RVPHW

GlobeNewswire

a year ago

Reviva Pharmaceuticals to Participate in the Lytham Partners Fall 2024 Investor Conference

RVPHW

Zacks Small Cap Research

a year ago

RVPH: RECOVER Biomarker KOL Event

Reviva Announces New Vocal Biomarker Data from Phase 3 RECOVER Trial of Brilaroxazine in Schizophrenia

RVPHW

GlobeNewswire

a year ago

Reviva Announces New Vocal Biomarker Data from Phase 3 RECOVER Trial of Brilaroxazine in Schizophrenia

Reviva to Participate in the H.C. Wainwright 26th Annual Global Investment Conference

RVPHW

GlobeNewswire

a year ago

Reviva to Participate in the H.C. Wainwright 26th Annual Global Investment Conference

Reviva to Host Virtual KOL Event to Discuss Vocal Biomarker Data from Phase 3 RECOVER Trial of Brilaroxazine in Schizophrenia on September 4, 2024

RVPHW

GlobeNewswire

a year ago

Reviva to Host Virtual KOL Event to Discuss Vocal Biomarker Data from Phase 3 RECOVER Trial of Brilaroxazine in Schizophrenia on September 4, 2024

RVPHW

Zacks Small Cap Research

a year ago

RVPH: August OLE Update

RVPHW

MT Newswires

a year ago

Top Midday Decliners

RVPHW

MT Newswires

a year ago

Reviva Pharmaceuticals Holdings Prices $5 Million Offering

Reviva Pharmaceuticals Announces Pricing of $5.0 Million Underwritten Offering Priced At-the-Market Under Nasdaq Rules

RVPHW

GlobeNewswire

a year ago

Reviva Pharmaceuticals Announces Pricing of $5.0 Million Underwritten Offering Priced At-the-Market Under Nasdaq Rules

Reviva Reports Second Quarter 2024 Financial Results and Recent Business Highlights

RVPHW

GlobeNewswire

a year ago

Reviva Reports Second Quarter 2024 Financial Results and Recent Business Highlights

Reviva Announces Grant of U.S. Patent Covering Use of Brilaroxazine for the Treatment of Idiopathic Pulmonary Fibrosis

RVPHW

GlobeNewswire

a year ago

Reviva Announces Grant of U.S. Patent Covering Use of Brilaroxazine for the Treatment of Idiopathic Pulmonary Fibrosis

Reviva Announces Grant of European Patent Covering Use of Brilaroxazine for the Treatment of Pulmonary Hypertension

RVPHW

GlobeNewswire

a year ago

Reviva Announces Grant of European Patent Covering Use of Brilaroxazine for the Treatment of Pulmonary Hypertension

Lotto 6/49 - $64 million up for grabs in the next draw!

RVPHW

CNW Group

a year ago

Lotto 6/49 - $64 million up for grabs in the next draw!

Returns On Capital At B&S Group (AMS:BSGR) Paint A Concerning Picture

RVPHW

Simply Wall St.

a year ago

Returns On Capital At B&S Group (AMS:BSGR) Paint A Concerning Picture

Seoul says it will resume loudspeaker propaganda against North

RVPHW

AFP

a year ago

Seoul says it will resume loudspeaker propaganda against North

It Might Not Be A Great Idea To Buy PATRIZIA SE (ETR:PAT) For Its Next Dividend

RVPHW

Simply Wall St.

a year ago

It Might Not Be A Great Idea To Buy PATRIZIA SE (ETR:PAT) For Its Next Dividend

OUTsurance Group Insiders Placed Bullish Bets Worth R25.5m

RVPHW

Simply Wall St.

a year ago

OUTsurance Group Insiders Placed Bullish Bets Worth R25.5m

Fed Meeting, Inflation Report, Apple’s WWDC, Broadcom Earnings, and More to Watch This Week

RVPHW

Barrons.com

a year ago

Fed Meeting, Inflation Report, Apple’s WWDC, Broadcom Earnings, and More to Watch This Week

Just Three Days Till BREMER LAGERHAUS-GESELLSCHAFT -Aktiengesellschaft von 1877- (FRA:BLH) Will Be Trading Ex-Dividend

RVPHW

Simply Wall St.

a year ago

Just Three Days Till BREMER LAGERHAUS-GESELLSCHAFT -Aktiengesellschaft von 1877- (FRA:BLH) Will Be Trading Ex-Dividend

An Intrinsic Calculation For ORIOR AG (VTX:ORON) Suggests It's 35% Undervalued

RVPHW

Simply Wall St.

a year ago

An Intrinsic Calculation For ORIOR AG (VTX:ORON) Suggests It's 35% Undervalued

Reviva Announces Closing of $3 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

RVPHW

GlobeNewswire

a year ago

Reviva Announces Closing of $3 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

RVPHW

MT Newswires

a year ago

Riviva Pharmaceuticals Prices $3 Million Offering of Stock, Warrants; Shares Slump

Reviva Announces $3 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

RVPHW

GlobeNewswire

a year ago

Reviva Announces $3 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

RVPHW

Zacks Small Cap Research

a year ago

RVPH: Enrollment Right Around the Corner

Reviva to Participate in the BIO International Convention

RVPHW

GlobeNewswire

a year ago

Reviva to Participate in the BIO International Convention

RVPHW

GlobeNewswire

a year ago

Reviva Announces Enrollment Update for Open Label Extension Study Evaluating Brilaroxazine in Schizophrenia

Reviva Reports First Quarter 2024 Financial Results and Recent Business Highlights

RVPHW

GlobeNewswire

a year ago

Reviva Reports First Quarter 2024 Financial Results and Recent Business Highlights

Reviva to Present New Preclinical Efficacy Data on Brilaroxazine in Idiopathic Pulmonary Fibrosis at 2024 ATS International Conference

RVPHW

GlobeNewswire

a year ago

Reviva to Present New Preclinical Efficacy Data on Brilaroxazine in Idiopathic Pulmonary Fibrosis at 2024 ATS International Conference

Reviva to Present New Non-Clinical Pharmacology Data on Brilaroxazine at the ASPET 2024 Annual Meeting

RVPHW

GlobeNewswire

a year ago

Reviva to Present New Non-Clinical Pharmacology Data on Brilaroxazine at the ASPET 2024 Annual Meeting

RVPHW

Zacks Small Cap Research

a year ago

RVPH: Full Year 2023 Results

Reviva Announces FDA Alignment on Brilaroxazine Clinical Trials for NDA in Schizophrenia

RVPHW

GlobeNewswire

a year ago

Reviva Announces FDA Alignment on Brilaroxazine Clinical Trials for NDA in Schizophrenia

Reviva Reports Full Year 2023 Financial Results and Recent Business Highlights

RVPHW

GlobeNewswire

a year ago

Reviva Reports Full Year 2023 Financial Results and Recent Business Highlights

RVPH: Update to Brilaroxazine Safety vs. Efficacy Comparison – Adding RECOVER Data

RVPHW

Zacks Small Cap Research

a year ago

RVPH: Update to Brilaroxazine Safety vs. Efficacy Comparison – Adding RECOVER Data

Reviva to Present RECOVER Phase 3 Clinical Trial Data for Brilaroxazine in Schizophrenia at the SIRS 2024 Annual Meeting

RVPHW

GlobeNewswire

a year ago

Reviva to Present RECOVER Phase 3 Clinical Trial Data for Brilaroxazine in Schizophrenia at the SIRS 2024 Annual Meeting

Reviva to Present RECOVER Phase 3 Clinical Trial Data for Brilaroxazine in Schizophrenia at the ASCPT 2024 Annual Meeting

RVPHW

GlobeNewswire

a year ago

Reviva to Present RECOVER Phase 3 Clinical Trial Data for Brilaroxazine in Schizophrenia at the ASCPT 2024 Annual Meeting

Reviva to Present at the UBS Virtual CNS Day

RVPHW

GlobeNewswire

a year ago

Reviva to Present at the UBS Virtual CNS Day

Reviva to Present at the 36th Annual ROTH Conference

RVPHW

GlobeNewswire

a year ago

Reviva to Present at the 36th Annual ROTH Conference

Reviva Pharmaceuticals to Present at the 2024 BIO CEO & Investor Conference

RVPHW

GlobeNewswire

a year ago

Reviva Pharmaceuticals to Present at the 2024 BIO CEO & Investor Conference

Reviva to Host KOL Event to Discuss Topline Data from Phase 3 RECOVER Trial of Brilaroxazine in Schizophrenia

RVPHW

GlobeNewswire

2 years ago

Reviva to Host KOL Event to Discuss Topline Data from Phase 3 RECOVER Trial of Brilaroxazine in Schizophrenia

NanoString Launches the CosMx 6,000 plex RNA Assay and Showcases Whole Transcriptome Imaging Capability

RVPHW

Business Wire

2 years ago

NanoString Launches the CosMx 6,000 plex RNA Assay and Showcases Whole Transcriptome Imaging Capability

Boston Scientific Surges To A Record On Its 'Impressive' First-Quarter Guidance

RVPHW

Investor's Business Daily

2 years ago

Boston Scientific Surges To A Record On Its 'Impressive' First-Quarter Guidance

J.P. Morgan & Fidelity Reports: Realistic Retirement Rate of Return By Asset Class

RVPHW

SmartAsset

2 years ago

J.P. Morgan & Fidelity Reports: Realistic Retirement Rate of Return By Asset Class

Cemtrex Receives $3.8 Million for Two Advanced Industrial Services Projects

RVPHW

GlobeNewswire

2 years ago

Cemtrex Receives $3.8 Million for Two Advanced Industrial Services Projects

Merchants Bancorp Full Year 2023 Earnings: Beats Expectations

RVPHW

Simply Wall St.

2 years ago

Merchants Bancorp Full Year 2023 Earnings: Beats Expectations

The Fixed Broadband Market in Asia-Pacific, 2023: Growth Drivers, Revenue Trends, Regional Opportunities

RVPHW

GlobeNewswire

2 years ago

The Fixed Broadband Market in Asia-Pacific, 2023: Growth Drivers, Revenue Trends, Regional Opportunities

Gas prices in 'glacial grind higher' for now — here's why

RVPHW

Yahoo Finance

2 years ago

Gas prices in 'glacial grind higher' for now — here's why

TransCode Therapeutics and Debiopharm Announce Collaboration to Develop Targeted Nucleic Acid Therapeutics for Cancer

RVPHW

GlobeNewswire

2 years ago

TransCode Therapeutics and Debiopharm Announce Collaboration to Develop Targeted Nucleic Acid Therapeutics for Cancer

Trump vs. Biden: How the 2024 election could affect Exxon, Nvidia, and other stocks

RVPHW

Yahoo Finance

2 years ago

Trump vs. Biden: How the 2024 election could affect Exxon, Nvidia, and other stocks

Reviva Pharmaceuticals to Participate in a Fireside Chat at the Lytham Partners 2024 Investor Select Conference

RVPHW

GlobeNewswire

2 years ago

Reviva Pharmaceuticals to Participate in a Fireside Chat at the Lytham Partners 2024 Investor Select Conference

VERB's MARKET.live Announces the Addition of 5 More Distinctive Retail Brands to its Livestream Social Shopping Platform

RVPHW

GlobeNewswire

2 years ago

VERB's MARKET.live Announces the Addition of 5 More Distinctive Retail Brands to its Livestream Social Shopping Platform

Brain Disease Cures: 3 Neuroscience Stocks Targeting Revolutionary Breakthroughs

RVPHW

InvestorPlace

2 years ago

Brain Disease Cures: 3 Neuroscience Stocks Targeting Revolutionary Breakthroughs

RVPHW

GuruFocus.com

2 years ago

AGNC Investment Corp (AGNC) Reports Solid Q4 Earnings Amid Market Volatility

RVPHW

Associated Press Finance

2 years ago

AGNC Investment: Q4 Earnings Snapshot

Soluna Secures 8.8 MW Hosting Deal with Leading Bitcoin Miner

RVPHW

Business Wire

2 years ago

Soluna Secures 8.8 MW Hosting Deal with Leading Bitcoin Miner

Versus Systems Regains Compliance with Nasdaq Minimum Bid Price Requirement

RVPHW

GlobeNewswire

2 years ago

Versus Systems Regains Compliance with Nasdaq Minimum Bid Price Requirement

Cenntro Electric Group Encourages All Shareholders to Vote in Favor of Proposed Scheme Resolution to Redomicile from Australia to the United States

RVPHW

Business Wire

2 years ago

Cenntro Electric Group Encourages All Shareholders to Vote in Favor of Proposed Scheme Resolution to Redomicile from Australia to the United States

Cohen & Company Capital Markets Highlights Strong 2023

RVPHW

PR Newswire

2 years ago

Cohen & Company Capital Markets Highlights Strong 2023

Vision Sensing Acquisition Corp. Announces Definitive Agreement and Plan of Merger with Mediforum Co., Ltd

RVPHW

GlobeNewswire

2 years ago

Vision Sensing Acquisition Corp. Announces Definitive Agreement and Plan of Merger with Mediforum Co., Ltd

Soluna to Participate in Water Tower Research Fireside Chat Series

RVPHW

Business Wire

2 years ago

Soluna to Participate in Water Tower Research Fireside Chat Series

EV maker VinFast bets its US future on $20,000 car with 'an interesting twist'

RVPHW

Yahoo Finance

2 years ago

EV maker VinFast bets its US future on $20,000 car with 'an interesting twist'

Reviva to Present at Webull LIVE! Healthcare Webinar on January 17

RVPHW

ACCESSWIRE

2 years ago

Reviva to Present at Webull LIVE! Healthcare Webinar on January 17

RVPHW

Zacks Small Cap Research

2 years ago

TLSA: First Phase II SPMS Patient Dosed

$572 Million Business Combination Between Braiin and Northern Revival Acquisition Corporation (Nasdaq: NRAC) Has Been Proposed and Form F-4 Jointly Filed With SEC

RVPHW

Business Wire

2 years ago

$572 Million Business Combination Between Braiin and Northern Revival Acquisition Corporation (Nasdaq: NRAC) Has Been Proposed and Form F-4 Jointly Filed With SEC

Reviva Provides Corporate and Program Updates and Highlights Key Upcoming Milestones

RVPHW

GlobeNewswire

2 years ago

Reviva Provides Corporate and Program Updates and Highlights Key Upcoming Milestones

Versus Systems Announces Annual General Meeting Results

RVPHW

GlobeNewswire

2 years ago

Versus Systems Announces Annual General Meeting Results

Investigator-initiated Phase 1/2 Clinical Trial Using Salarius Pharmaceuticals’ Seclidemstat in Combination with Azacitidine to Treat Hematologic Cancers Resumes Patient Enrollment

RVPHW

GlobeNewswire

2 years ago

Investigator-initiated Phase 1/2 Clinical Trial Using Salarius Pharmaceuticals’ Seclidemstat in Combination with Azacitidine to Treat Hematologic Cancers Resumes Patient Enrollment

Trio Petroleum Corp Announces Commencement of Production of Two Wells - its HV-1 Confirmation Well and its HV-3A Discovery Well in the South Salinas Project

RVPHW

GlobeNewswire

2 years ago

Trio Petroleum Corp Announces Commencement of Production of Two Wells - its HV-1 Confirmation Well and its HV-3A Discovery Well in the South Salinas Project

Latest Reviva Pharmaceuticals Holdings Inc. (RVPHW) News on August 13, 2025

Share on Social Networks: